wherein L and R_2 are as defined herein, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.

[0008] Another aspect of the present invention is directed to a pharmaceutical composition that includes a therapeutically effective amount of a compound of formula (I) or (II) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical composition comprises a co-crystal of the compound.

[0009] A further aspect of the present invention is directed to methods of treating diseases or disorders that would benefit from IKZF2 (Helios) degradation.

[0009a] In another aspect, there is provided a use of a compound or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof as described herein in the manufacture of a medicament for the treatment of a disease or disorder that is associated with IKZF2 (Helios) and would benefit from IKZF2 degradation.

[0010] In some embodiments, the disease or disorder is cancer. In some embodiments, the cancer is T cell leukemia, T cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, myeloid leukemia, non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, or carcinoid.

[0011] As demonstrated in the working examples, compounds of the present invention exhibit potent degradation of IKZF2 (Helios).

[0012] Although not intending to be bound by any particular theory of operation, it is believed that inventive compounds may enhance an anti-tumor immune response by enabling regulatory T cells to assume functions of effector T cells, and by rescuing effector T cell function in exhausted T cells or CAR-T cells.

BRIEF DESCRIPTION OF THE DRAWINGS

[0013] FIG. 1A-FIG. 1C are plots of the cellular IKZF2-degradation green fluorescent protein (GFP) assay for inventive compounds 36, 72, and 79, where IC_{50} values show the combinatorial effect of cell permeability and compounds' ability to degrade IKZF2 in the cell.

DETAILED DESCRIPTION OF THE INVENTION

[0014] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the subject matter herein belongs. As used in the specification and the appended claims, unless specified to the contrary, the following terms have the meaning indicated in order to facilitate the understanding of the present invention.